TradersLink
$NTHISep 22, 2026, 2:52 PM ETAI processed

NeOnc (NTHI) reports positive Phase 2a intranasal NEO100 data in IDH1‑mutant high‑grade glioma

AI Summary

NeOnc (NTHI) reported Phase 2a results for intranasal NEO100 in recurrent/progressive Grade III/IV IDH1‑mutant glioma: six‑month PFS 48.9% versus a prespecified 20% benchmark (p=0.0047), median OS 26.09 months, with no major toxicities and mostly low‑grade adverse events (5 of 24 patients still on treatment at cutoff). The company plans to seek a Type B FDA meeting to discuss a potential registrational pathway, but the data are from a small (n=24), single‑arm study and will need confirmation in larger, controlled trials within a challenging glioma landscape.

Positives

  • Phase 2a showed six‑month PFS 48.9% vs 20% prespecified benchmark (p=0.0047)
  • Median overall survival reported at 26.09 months with no major toxicities and mostly low‑grade AEs
  • Company intends to request a Type B meeting with FDA to discuss registrational pathway

Negatives

  • Small cohort (24 patients) from a single‑arm study limits robustness and generalizability
  • No randomized or controlled comparator — results are preliminary and require confirmation
  • Glioma development path is competitive and historically difficult to translate into positive registrational outcomes